You Searched For "merck stock price" and got 19 results
Sort By:
1 min read
Retail investors are dumping shares of COVID-19 vaccine makers and piling into antiviral pill maker Merck, data shows
Merck shares have jumped since the drug maker said molnupiravir cuts the risk of COVID hospitalizat…
Carla Mozée
2 mins read
A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year
Bob Duggan, 80, has gone from baking cookies to building robots, investing in biotech companies, an…
Theron Mohamed
2 mins read
Merck jumps 10% as the drugmaker says its antiviral pill cuts the risk of hospitalizations and deaths in COVID patients
Merck already has a deal to supply 1.7 million courses of antiviral pill molnupiravir to the US gov…
Carla Mozée
2 mins read
Moderna spikes 19% amid a flood of encouraging vaccine news, surpassing Merck in market value
Moderna, the almost 11 year old company that created a 95% effective pandemic ending vaccine in les…
Matthew Fox
1 min read
Pandion Therapeutics soars 132% after Merck agrees to buy the biotech for $1.85 billion
Pandion is a clinical-stage biotechnology company that is developing therapeutics for patients livi…
Matthew Fox
1 min read
Moderna and BioNTech plummet more than 15% following news of Merck's COVID-19 antiviral pill
The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still strugg…
Matthew Fox
1 min read
Merck sells its investment stake in Moderna after recording a 'substantial' gain
Merck initially invested $50 million in Moderna before it was public in 2015, and subsequently inve…
Matthew Fox
2 mins read
Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.
Buffett's company established stakes in Merck, AbbVie, and Bristol Myers Squibb in the second half …
Theron Mohamed
2 mins read
Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine
The move is welcomed by investors because if successful, it would help Moderna diversify its revenu…
Matthew Fox
2 mins read
Dogecoin, Merck's antiviral pill, and Nicole Kidman: Here's what AMC CEO and meme-stock icon Adam Aron has been talking about
The AMC chief executive caught the attention of Tesla's Elon Musk and billionaire investor Mark Cub…
Natasha Dailey
2 mins read
Moderna, BioNTech tumble 19% amid report the EU is looking into COVID vaccine side effects
The EU's drug regulator is looking at reports about skin rash and kidney problems.
Carla Mozée
4 mins read
Merck is set to make billions off a COVID-19 pill that could change the pandemic. Here's why some countries will pay more than others.
Merck's antiviral has not yet been authorized, but the company already has plans to distribute the …
Andrew Dunn
1 min read
Moderna and Pfizer rebound after FDA authorizes third COVID-19 booster shot for immunocompromised
Year-to-date, shares of BioNTech, Moderna, and Pfizer have surged 357%, 275%, and 28%, respectively.
Matthew Fox
2 mins read
'From unreasonable to ridiculous': Here's why Moderna is set to fall 76%, according to Bank of America
"To justify $200 billion in value, one has to assume 1 to 1.5 billion doses of COVID-19 vaccine eac…
Matthew Fox
1 min read
Pfizer jumps 6% to eclipse record high reached in 1999 as strength from COVID-19 vaccine continues
Shares of Pfizer jumped to a high of $48.57 on Tuesday, more than a dollar higher than its previous…
Matthew Fox
2 mins read
Verizon climbs 4% after Warren Buffett reveals nearly $9 billion investment
Berkshire Hathaway added 147 million of Verizon's shares to its holdings in the December quarter, a…
Ben Winck
1 min read
Merck CEO Kenneth Frazier is retiring. He is one of only 4 Black CEOs in the Fortune 500, and famously stood up to Trump over Charlottesville in 2017.
Kenneth Frazier, who has led the US pharma giant Merck for nearly 30 years, is retiring, and will b…
Kate Duffy,Reuters
3 mins read
US stocks trade mixed as investors weigh strong earnings against stimulus holdup
The S&P 500 sank by the most in a month on Monday as new COVID-19 cases hit a record and stimulus h…
Ben Winck
2 mins read
Inovio's 860% year-to-date rally takes a breather after the release of Phase I data for company's COVID-19 vaccine candidate
Inovio's Tuesday morning release of early-stage data on its COVID-19 vaccine candidate sent shares …